



Cutaneous Lymphomas: Insights & Therapeutic Progress

Hilton London Tower Bridge Hotel
5 More London Place, Tooley Street, London SE1 2BY

Pre-Meeting Events:

Thursday 12 October 2017 Guy's Hospital Campus

16:30-18:00 ProCLIPi meeting	Guys Tower Wing 30th Floor Lecture Theatre
18:15-19:00 EORTC CLTF board meeting	Guys Tower Wing 9th Floor Seminar Room
18:15-19:00 UKCLG business meeting	Guys Tower Wing 8th Floor Seminar Room

Friday 13 October 2017

08:30-12:30 CL International Nursing Network	Guy's Cancer Centre Innovation Hub
07:00-12:00 Advisory Boards	Conference venue
11.30-12.15 ISCL board meeting	Conference venue

**Main Meeting Scientific Programme
Friday 13 October 2017**

11.00-12.30 Registration

12.30 Welcome

Sean Whittaker & Pietro Quaglino

12.30-13.30 Lunch & Sponsored Symposium – ACTELION

LEDAGA® (chlormethine) gel: the first topical therapy specifically licensed for MF-CTCL in Europe

Chair: M Bagot; J Scarisbrick; Y Kim

13:30-14:30 Biologic Insights (I) (Chairs: Whittaker; Quaglino; Willemze)

O-01. Genetic landscape of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg-type

A. Pham-Ledard, S. Mareschal; M. Prochazkova-Carlotti, M. Beylot-Barry, P. Joly, P.J. Vially, S. Dubois, P. Bertrand, J-P Merlio, F. Jardin (Bordeaux, France)

O-02. Exome sequencing of skin-limited mycosis fungoides

A. de Masson, E. Lowry, C.P. Elco, A. Thorner, R.A. Clark, T.S. Kupper (Boston, USA)

O-03. Next Generation Sequencing using a Tumour Panel in Macrodissected Tumour Cells from Plaque/Tumour Mycosis fungoides in Treatment Naïve Patients

J. Yoo, M. Forfouace, K. Hartmann, J-B. Cazier, B. Noyvert, A. Beggs, M. Vermeer, F. Shah, P. Moss, J. Scarisbrick (Birmingham, UK – EORTC – Leiden, the Netherlands)

O-04. Genomic Analysis of 220 CTCLs Identifies a Novel Recurrent Gain-of-function Alteration in RLTPR (p.Q575E)

J. Park, J. Yang, A.T. Wenzel, A. Ramachandran, W.J. Lee, J.C. Daniels, J. Kim, E. Martinez-Escala, N. Amankulor, B. Pro, J. Guitart, M.L. Mendillo, J.N. Savas, T.J. Boggon, J. Choj (Chicago; Pittsburgh; New Haven, USA)

O-05. Interrogation of a role for dysfunction of Pot 1 in primary Cutaneous T-cell Lymphoma

F. Bakr, A. Cox, L. Goodwill, C. Jones, S.J. Whittaker, T.J. Mitchell (London, UK)

14:30-15:00 Guest Lecture: Francesca Ciccarelli (CRICK Institute and Kings College London)

15:00-15:30 *Tea/Coffee Break/Poster Viewing and Exhibition*

15:30-16:00 Guest Lecture: Adrian Hayday (CRICK Institute and Kings College London)

16:00-18:15 Biologic Insights (II) (Chairs: Mitchell; Vermeer; Bagot)

O-06. RAD23B and Signal Transducer and Activator of Transcription 3 (STAT3): interacting mediators of Histone Deacetylase inhibitor (HDACi) response in Cutaneous T cell Lymphoma (CTCL)?

R.M. Butler, R.T. McKenzie, S.J. Whittaker, T.J. Mitchell (London, UK)

O-07. A TAK1-dependent pro-survival pathway supports human cutaneous T-cell lymphoma

F. Gallardo, J. Bertran, E. López-Arribillaga, J. González, M. Iglesias, R.M. Pujol, A. Bigas, L. Espinosa (Barcelona, Spain)

O-08. Deregulated mechanisms downstream of PLCG1 promoting Cutaneous T Cell Lymphoma progression

N.García-Díaz, C. Pérez, A.A. Gru, R. Alonso-Alonso, R. Mondejar, L. Cereceda, P. Ortiz-Romero, M.Á. Piris, J.P. Vaqué (Cantabria, Spain)

O-09. Identification and validation of PPP5C mutations in Cutaneous T-cell lymphoma (CTCL)
C. Flanagan, S. Whittaker, T. Mitchell (London, UK)

O-10. Sézary cells: clonal but versatile

M. Roelens, C. Ram-Wolff, M. Delord, A. Marie-Cardine, A. Alberdi, A. Bensussan, M. Bagot, A. Toubert, H. Moins-Teisserenc (Paris, France)

O-11. The immune checkpoint landscape of mycosis fungoides

D.J. Murray, R. Amez-Kashpaz, N. Davies, S. Eldershaw, J. McMurray, H. Pearce, P. Roberts, H. Pybus, P. Moss, J. Scarisbrick (Birmingham, UK)

O-12. Role of dysregulated cytokine signalling and bacterial triggers in the pathogenesis of Cutaneous T Cell Lymphoma

M.H. Fanok, A. Sun, L. Fogli, V. Narendran, M. Eckstein, J-A Latkowski, N. Odum, K. Hymes, S. Goel, S. Koralov (New York, USA)

O-13. Mycosis fungoides, delineating the cytokine production between tumour and tumour infiltrating lymphocyte

J. McMurray, D. Murray, H. Pearce, S. Eldershaw, N. Davies, P. Moss, J. Scarisbrick (Birmingham, UK)

O-14. Programmed cell death ligand 1 and programmed cell death ligand 2 locus and protein expression in primary cutaneous diffuse large B-cell lymphoma, leg type

S. Menguy, M. Prochazkova-Carlotti, M. Beylot-Barry, B. Vergier, J-P. Merlio, A. Pham-Ledard (Bordeaux, France)

O-15. PD-L1 Regulation in Cutaneous T cell Lymphoma

S.Hee Kil, R. Estephan, J. Sanchez, J. Zain, M. Kadin, S.T. Rosen, C. Querfeld (Duarte, USA)

O-16. CD47 Blockade with TTI-621 (SIRPαFc) in Sézary Syndrome

O.E. Akilov, S. Banerjee, A.M. O'Connor, H. Chen, B. Bossen, N. Nielsen Viller, R.A. Uger, M. Wong, L. Johnson (Pittsburgh, USA; Mississauga, Canada)

18:30-20:30

Welcome Social Reception

Gordon Museum King's College Guy's Campus

Saturday 14 October 2017

08:00-10:00 Diagnostics and Biomarkers I (Chairs: Calonje; Knobler; Cozzi)

O-17. Gene expression analysis in CTCL highlights disease heterogeneity and identifies potential diagnostic and prognostic indicators

I.V. Litvinov, M.T. Tetzlaff, E. Rahme, V.G. Prieto, D. Sasseville, M. Duvic (Ottawa, Canada)

O-18. Activated Signal transducer and activator of transcription 3 is a biomarker of progression in Cutaneous T cell Lymphoma

R. Mondejar, C. Pérez, L. Cereceda, R. Alonso, N. García, P. Ortiz, G. Pérez-Paredes, J.P. Vaqué, M.A. Piris (Santander; Madrid, Spain)

O-19. High throughput sequencing of the T cell receptor B gene reliably predicts progression in patients with early stage Cutaneous T Cell Lymphoma

A. de Masson, J.T. O'Malley, I.L. Kirsch, H. Robins, R.A. Clark, T.S. Kupper (Boston, USA)

O-20. High SUV uptake on PET predicts for nodal large cell transformation in Mycosis Fungoides/Sezary Syndrome in a small prospective study

D. Blunt, K. Imrie, M. Cheung, N. Shear, Z. Ghorab, E. Piliotis (Toronto, Canada)

O-21. Histopathological features of initial skin biopsies of mycosis fungoides patients in intermediate T-stages

U. Wehkamp, V. Dessert, T. Schwarz, W. Klapper, I. Oschlies, M. Weichenthal (Kiel, Germany)

O-22. The Use of Digital Slide Scanning as a Tool for Central Pathology Review in Patients with Advanced Stage Mycosis Fungoides and Sezary Syndrome for the Prospective PROCLIP Study

A.A. Gru, M. Battistella, J. Kim, M. Pulitzer, J. Guitart, E. Hong, N.L. Harris, A. Feldman, Y. Kim (Charlottesville; Palo Alto; New York; Chicago; Boston; Rochester, USA - Paris, France – Birmingham, UK)

O-23. Prognostic Factors in Early Stage Mycosis Fungoides: The PROCLIP Study

J. Scarisbrick, P. Quaglino, M. Vermeer, E. Papadavid, E. Hodak, S. Whittaker, O. Servitje, E. Berti, F. Evison, Y. Kim, R. Willemze (Birmingham; London, UK – Torino; Milan, Italy – Leiden, the Netherlands – Athens, Greece – Tel Aviv, Israel – Barcelona, Spain - Stanford, USA)

O-24. How frequent is blood involvement in early mycosis fungoides?

H. Prag Naveh, S. Sherman Bergman, A. Nosrati Perchik, I. Amitay-Laish, Y. Shahal-Zimra, E. Hodak (Petach Tikva; Tel Aviv, Israel)

O-25. Correlation of B Class and MSWAT over time in individual patients with mycosis fungoides and Sézary syndrome: Variations in B class are not reflected by changes in skin tumour burden as measured by MSWAT

A. Wernham, J. Yoo, F. Shah, S. Chaganti, A. Stevens, M. Drayson, J. Scarisbrick (Birmingham, UK)

O-26. Clinicopathologic and cytogenetic reassessment of primary cutaneous follicular lymphomas compared to primary cutaneous marginal zone lymphomas: STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities are useful to segregate both entities

V. Szablewski, E. Verdant, C. René, E. Frouin, V. Cacheux, O. Dereure (Montpellier, France)

10:00-10:30

Tea/Coffee Break/Poster Viewing and Exhibition

10:30-11:15 Diagnostics and Biomarkers II (Chairs: Child; Gallop Evans; Stadler)

O-27. Biomarkers of pharmacological and clinical activity of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in a Phase I study in patients with relapsed/refractory Cutaneous T-cell Lymphomas (CTCL)

M. Battistella, A. Marie-Cardine, C. Paturel, C. Bonnafous, N. Thonnart, M. Khodadoust, A. Widemann, M. Bagot, Y. H. Kim, P. Porcu, C. Ram-Wolff, B.M. William, S. Mathieu, M. Vermeer, S. Whittaker, A. Bensussan, A. Dujardin, C. Paiva, K. Pilz, H. Sicard (Paris; Marseille, France - Palo Alto; Philadelphia; Columbus; Houston, USA - Leiden, The Netherlands - London, UK)

O-28. Brentuximab Vedotin vs Physician's Choice in Patients with Cutaneous T Cell Lymphoma (CTCL) from the Phase 3 ALCANZA study: Analysis of Outcomes by CD30 Expression

Y.H. Kim, H.M. Prince, S. Whittaker, S.M. Horwitz, M. Duvic, J. Scarisbrick, P. Quaglino, P.L. Zinzani, P. Wolter, O. Bechter (Stanford; New York; Houston; USA – Melbourne, Australia – London; Birmingham, UK - Leuven, Belgium – Turin; Bologna, Italy)

O-29. Utility of imaging in cutaneous follicle center lymphoma*

S. Geller, M. Pulitzer, P. Myskowski, A. Moskowitz, S. Horwitz, M. Kheterpal (New York, USA)

* Joint discussion

O-30. Utility of imaging in cutaneous marginal zone lymphoma*

M. Kheterpal, S. Geller, J. Dai, M. Pulitzer, P. Myskowski, A. Moskowitz, J. Kim, R. Hoppe, Y. Kim, S. Horwitz (New York, USA)

O-31. Adult T-cell leukemia/lymphoma in a tertiary institution in São Paulo, Brazil

D. Miyashiro, R. Vasconcelos-Berg, J. Cury-Martins, A.N.R. Abdo, J. Pereira, J A. Sanches (São Paulo, Brazil)

11:15-12:15 Clinical Outcomes and Quality of Life (Chairs: Child; Gallop Evans; Stadler)

O-32. Illness perception and psychological aspects among Mycosis Fungoides patients

O. Segal, N. Trumper, G. Goldzweig, A. Barzilai (Tel-Hashomer; Tel Aviv; Jaffa, Israel)

O-33. Implementing the Cutaneous T-cell Lymphoma-Quality of Life Instrument in Clinical Practice

R.N. Matin (Oxford, UK)

O-34. "It's a traumatic illness, traumatic to witness." A qualitative study of the experiences of bereaved family caregivers of patients with cutaneous T-cell lymphoma

D. Orlowska, L. Selman, T. Beynon, E. Radcliffe, S. Whittaker, F. Child, R. Harding (London, UK)

O-35. First-Line Treatment and Responses in Early Stage Mycosis Fungoides: Results of PROspective Cutaneous Lymphoma International Study (PROCLIP Study)

P. Quaglino, M. Vermeer, H.M. Prince, E. Papadavid, F. Child, M. Bagot, R. Stadler, R. Knobler, F. Evison, J. Scarisbrick (Turin, Italy – Leiden, Netherlands – Melbourne, Australia – Athens, Greece – London; Birmingham, UK – Paris, France – Minden, Germany – Vienna, Austria)

O-36. Thinking about CNS Metastasis in Cutaneous Lymphoma: Analysis of Existing Data

Y. Yang, H. Wickless (Dallas, USA)

12.15-12.30 *Comfort Break*

12:30-13:30 Lunch & Sponsored Symposium – TAKEDA

CD30 testing in cutaneous T-cell lymphoma: an important step in diagnosis and treatment

Chair: *H.M Prince; J Scarisbrick; S Morris*

13.30-13.45 *Comfort Break*

13:45-14:30 Neil Smith Memorial Lecture: Rafael Duarte (Madrid)

14:30-15:30 Therapeutics (I) (Chairs: Morris; Cowan; Scarisbrick)

O-37. Determination of Molecular Remission in Patients with Mycosis Fungoides (MF) and Sézary Syndrome (SS) Following Allogeneic Transplant Using T-Cell Receptor High Throughput Sequencing (HTS)

T.H. Almazan, R. Armstrong, R. Hoppe, Y. H. Kim, W-K. Weng (Palo Alto, USA)

O-38. Allogeneic Stem Cell Transplantation for Advanced Cutaneous T-Cell Lymphoma with Minimal-Intensity Conditioning

R. Palanicawandar, S. Morris, S. Lozano-Cerrada, B. Sevillano Zamarreño, M. Wain, F. Child, S. Whittaker, E. Olavarria, E. Kanfer (London, UK)

O-39. Anti-CCR4 antibody mogamulizumab prior to allogeneic hematopoietic stem cell transplantation in patients with mycosis fungoides (MF) and Sézary syndrome (SS): Is there an increased risk for graft-versus-host-disease related complications?

J. Dai, T.H. Almazan, M.S. Khodadoust, J-P Okhovat, W-K Weng, Y-H Kim (Palo Alto, USA)

O-40. Comparative analysis of low dose vs high dose of Total Skin Electron Beam Irradiation (TSEBI) in 85 patients with Mycosis Fungoides/Sezary Syndrome (MF) treated between 1996 and 2016

A. Arellano, R. Ballester, I. Bielsa, J. Bassas, O. Servitge, P. García-Muret, T. Estrach, R. Izu, R. Pujol, J. Jové, (Barcelona; Bilbao, Spain)

O-41. A Single-Arm phase 2A study of NM-IL-12 (rHu-IL12) in patients with mycosis Fungoides –Type CTCL (MF) undergoing low-dose total skin electron beam therapy (LD-TSEBT)

Y.H. Kim, R.T. Hoppe, A.H. Rook, A. Maity, L. Geskin, D. Horowitz, G. Finnegan, M. Khodadoust, W-K Weng, A. Lares, E.K. Hong, M. Buchanan, H. Kha, C.E. Lawrence, V. Vainstein, L.A. Basile (Stanford; Pennsylvania, USA)

15:30-16:00

Tea/Coffee Break/Poster Viewing and Exhibition

16:00-17:30 Therapeutics (II) (Chairs: Guenova; Ortiz; Wain)

O-42. Treatment of mycosis fungoides and Sézary syndrome by Romidepsin: a series of 32 cases of the French Group Study of Cutaneous Lymphoma (GFELC)

O. Deschamps, C. Ram-Wolff, M. Beylot-Barry, F. Grange, F. Skowron, O. Dereure, S. Boulinguez, F. Aubin, S. Oro, M. Bagot (Paris; Bordeaux; Reims; Valence; Montpellier; Toulouse; Besançon; Créteil; Paris, France)

O-43. A Review of the Experience of Histone Deacetylase inhibitors in the Mycosis Fungoides (MF) and Sézary Syndrome (SS) Cohorts of Primary Cutaneous T-cell lymphoma at the Peter MacCallum Cancer Centre, Melbourne, Australia

T. Papps; C. Van Der Weyden; R. Twigger; C. McCormack; H.M. Prince; (Melbourne, Australia)

O-44. Phase 1 Trial Evaluating MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients

C. Querfeld, F. Foss, L. Pinter-Brown, P. Porcu, B.M. William, T. Pacheco, B. Haverkos, Y. Kim, J. Guitart, A. Halwani (Duarte, USA)

O-45. Cutaneous lymphomas in patients treated by biologics: 21 cases of GFELC

M. Beylot-Barry; L. Dequidt, H. Adamski; S. Boulinguez, S. Dalle, S. Oro, N. Bonnet, B. Cortès, F. Grange, G. Quereux, C. Ram-Wolff, F. Skovron, L. Verneuil, N.Franck (Bordeaux; Rennes; Lyon Sud; Toulouse; Créteil; Marseille; Reims; Nantes; Valence; Paris; Caen, France - Genève, Switzerland)

O-46. Low-dose subcutaneous alemtuzumab therapy followed by extracorporeal photopheresis in patients with Sezary syndrome or erythrodermic mycosis fungoides

C. van der Weyden, A. Khot, M. Dickinson, D. Westerman, C. McCormack, O. Buelens, C. Dowsing, H.M. Prince (Melbourne, Australia)

O-47. Updated Analyses of the International, Open-label, Randomized, Phase 3 ALCANZA Study: Longer-term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-positive Cutaneous T-cell Lymphoma

J. Scarisbrick, S.M. Horwitz, R. Dummer, M. Duvic, Y.H. Kim, J. Walewski, S. Whittaker, P. Quaglino, P.L. Zinzani, P. Wolter, H. Eradat, J. Sanches, P. Ortiz-Romero, O.E. Akilov, J. Trotman, K. Taylor, S. Dalle, M. Weichenthal, D.C. Fisher, R. Stadler, T. Feldman, T.M. Kuzel, A.A. Gru, Y. Wang, M.C. Palanca-Wessels, H-M Lin, Y. Liu, M. Little, H.M. Prince (Birmingham; London, UK - New York; Houston; Stanford; Los Angeles; Pittsburgh; Boston; Hackensack; Chicago; Charlottesville; Bothell; Cambridge, USA - Zürich, Switzerland – Warsaw, Poland – Turin; Bologna, Italy – Leuven, Belgium - São Paulo, Brazil – Madrid, Spain – Sydney; South Brisbane; Melbourne, Australia – Lyon, France – Kiel; Minden Germany)

O-48. Cardiovascular Mortality and Morbidity in Mycosis Fungoides and Sézary Syndrome

S. Tambone, M. P. Barrio, D.L. Pablos, C. Pellegrini, J.L.R. Peralto, M.C. Fargnoli, A.B. Echevarría, P.L. Ortiz Romero (L'Aquila, Italy – Madrid, Spain)

17:30 Young Investigator Awards (Chair: Guenova)

17:30-18:15 EORTC CLTF General Assembly and Trials Update

20:00 *Congress Dinner at The Honourable Artillery Company (HAC), City of London*

Sunday 15 October 2017

08:00-09:00 Breakfast & Sponsored Symposium - MALLINCKRODT

30 years of THERAKOS™ECP Immunomodulation

Chairs: J Scarisbrick/P Quaglino; E Guenova; R Knobler

09:00-10:15 Oral Poster Session (Chairs: EORTC board)

Session 1

OP-01. Evaluation of treatment results and long-term follow-up data of 31 patients with multifocal primary cutaneous anaplastic large cell lymphoma

R. Willemze, R.C. Melchers, M.H. Vermeer, K.D. Quint (Leiden, The Netherlands)

OP-02. Recommendations for the optimal radiation dose in patients with primary cutaneous anaplastic large cell lymphoma: A report of the Dutch Cutaneous Lymphoma Group

R.C. Melchers, K.D. Quint, R. Willemze, M.H. Vermeer, L.A. Daniëls, K.J. Neelis, M.W. Bekkenk, E.R.M. de Haas, B. Horvath, M.M. van Rossum (Leiden; Amsterdam; Rotterdam; Groningen; Nijmegen, The Netherlands)

OP-03. Activation Of Innate Immunity As A Strategy For CTCL Therapy

A.H. Rook, J.M. Gelfand, B. Benoit, A.B. Trowel, E. J. Kim, M. Wysocka, R.A. Clark (Pennsylvania; New York; Boston, USA)

OP-04. TIGIT Expression On Malignant T-Cells in Sezary Syndrome Is A Marker For Poor Immune Competency and Lack of Response To Immunotherapy

A.H. Rook, N. Jariwala, K.K. Zhang, B. Benoit, D.B. Shin, M. Wysocka (Pennsylvania, USA)

Session 2

OP-05. Challenges of blood classification and blood response criteria in mycosis fungoides and Sézary syndrome: Discussions and Recommendations following the EORTC Cutaneous Lymphoma Task Force Workshop

J. Scarisbrick, E. Hodak, M. Bagot, R. Stranzenbach, R. Stadler, P. Ortiz-Romero, E. Papadavid, R. Knobler, P. Quaglino, M. Vermeer (Birmingham, UK – Tel Aviv, Israel – Paris, France – Bochum, Germany – Madrid, Spain – Athens, Greece – Vienna, Austria – Turin, Italy – Leiden, The Netherlands)

OP-06. Cutaneous lymphoma international consortium: A prospective study in advanced stage mycosis fungoides and Sezary syndrome uniting international expert centres to evaluate and validate the prognostic index model

J. Scarisbrick, E. Hong, F. Evison, S. Whittaker, H.M. Prince, J. Sanches, S. Horwitz, P. Quaglino, M. Vermeer, Y.H. Kim (Birmingham; London, UK – Stanford; New York, USA – Melbourne, Australia – Sao Paulo, Brazil – Turin, Italy – Leiden, the Netherlands)

OP-07. Prevalence of T-cell antigens losses in mycosis fungoides and primary cutaneous CD30+ T-cell lymphoproliferative disorders: a retrospective study of 136 cases

J. Wechsler, S. Oro, J. Calderaro, N. Ortonne (Creteil, France)

OP-08. Tumor progression of folliculotropic mycosis fungoides is associated with increased miR-155 and Ki-67 expression and increased number of tumor-associated inflammatory cells

L. Atzmony, L. Moyal, M. Feinmesser, A. Hirshberg, I. Amitay-Laish, H. Prag-Naveh, E. Hodak (Petach Tikva; Tel Aviv; Herzeliya; Israel)

Session 3

OP-09. Comprehensive clinical, histopathological and molecular workup of 95 patients with primary cutaneous CD4+ small medium T-cell lymphoproliferative disorder

M. Wobser, M. Geiseler, S. Roth, M. Goebeler, A. Rosenwald, E. Geissinger, (Wuerzburg, Germany)

OP-10. Primary Cutaneous Small/Medium Cd4+ T-Cell Lymphoproliferative Disorder: A Spectrum Of Reactive Lymphoid Hyperplasia And Lymphomas

A. García-Herrera, M. Herrera, A. Valera, D. Soldini, A. Combalia, D. Colomer, A. López-Guillermo, G. Roncador, T. Estrach, E. Campo (Barcelona; Madrid, Spain – Locarno; Zurich, Switzerland)

OP-11. Single lesion T cells Follicular Helper proliferative disorders: about 70 cases

F. Beltzung, M. Beylot-Barry, M.D'Incan, S. Oro, F. Franck, J-P Merliot, N. Ortonne, B. Vergier (Clermont-Ferrand; Bordeaux; Créteil, France)

OP-12. A meta-analysis of exome sequencing in mature T-cell lymphoma

C.L. Jones, V. Pullabhatla, S.T. Whittaker, T.J. Mitchell (London, UK)

OP-13. Targeted deep sequencing analysis of primary cutaneous T-cell lymphomas not otherwise specified with TFH phenotype (PCTFHL) identifies mutations commonly present in angio-immunoblastic T-cell lymphomas.

N. Ortonne, N. Tazi, A. Pujals, R. Pelletier, L Pelletier, A. Dupuy, A. Carlotti, B. Balme, S. Oro, P. Gaulard (Creteil; Paris; Lyon, France)

Session 4

OP-14. Quinazoline T-cell proliferation inhibitor as a potential novel treatment for CTCL -An in vitro observational and mechanistic study

L. Moyal, V. Belozarov, B. Gorovitz, A. Levitzki, E. Igudin, I. Amitay-Laish, I. Lubin, M. Pasmanik-Chor, E. Hodak (Herzeliya; Tel Aviv, Israel)

OP-15. Evaluation of PI3K-mTOR inhibitors for cutaneous T-cell lymphomas treatment

A. Bresin, C. Cristofolletti, E. Caprini, M.H. Citterich, G. Russo, M.G. Narducci (Rome, Italy)

OP-16. Lenalidomide modulates cytokines' expression profile in Cutaneous T-cell Lymphoma cell lines

V. Bakou, A. Velentzas, F. Kontsioti, S. Papageorgiou, E. Bazani, I. Glezou, G. Stavroulaki, A. Bouchla, G. Dimitriadis, V. Pappa, E. Papadavid (Athens, Greece)

OP-17. A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study
R. Stadler, J. Scarisbrick, R. Knobler, P. Quaglino, M. Borgmann, M. Orlovius, B. Krauss, S. Danhauser-Riedl (Minden; Planegg-Martinsried, Germany – Birmingham, UK – Vienna, Austria – Torino, Italy)

OP-18. Resminostat's action in CTCL – hints from a genome-wide study
A.C. Bretz, T. Wulff, S. Schrepfer, K. Kronthaler, M. Borgmann, S. Hamm, (Planegg-Martinsried, Germany)

Session 5

OP-19. Maintenance treatment with Bexarotene in cutaneous T-cell lymphoma
A. Pileri, S. Gunnella, V. Grandi, I. Lastrucci, N. Pimpinelli (Bologna; Florence, Italy)

OP-20. Caregiver Burden and Quality of Life Factors Affecting Caregivers of Mycosis Fungoides/Sézary Syndrome Patients
S. McCann, J. Huwe, E. Astley, C. Lipner, A. Fabio, A. Apfel, O. Akilov (Pittsburgh, USA)

OP-21. Epidemiology of primary cutaneous lymphomas in the Czech Republic according to data of the Czech National Cancer Registry
J. Polivka, J. Muzik (Prague; Brno, Czech Republic)

OP-22. Clinical Service evaluation of the new iPad skin weighted assessment tool (iSWAT) for patients with Mycosis Fungoides
A. Kuciejewska, S Whittaker, C Chaptini, R Singer, A. Connolly, F. Child, M. Wain, S.L. Morris (London, UK)

OP-23. Risk of venous thromboembolism in mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study
L.M. Lindahl, M. Schmidt, D.K. Farkas, A.H. Rittig, H.T. Sørensen, L. Iversen, (Aarhus, Denmark)

Session 6

OP-24. Screening Value of Circulating TNFR1, TNFR2, and IL-12p70 for Diagnosis of Early Mycosis Fungoides
O.E. Akilov, A.E. Lokshin, L.K. Ferris, T. Sun, J.H. Jeong, L.D. Falo Jr, L.J. Geskin (Pittsburgh; New York, USA)

OP-25. Core-biopsy versus excisional biopsy for lymph node assessment in patients with Mycosis Fungoides and Sézary Syndrome
J. Cury-Martins, S. Dias do Couto Netto, S.C. Carqueijo de Castro, M.C. Nogueira Zerbini, S.A. Coelho Siqueira, J. Pereira, J.A. Sanches Jr (São Paulo, Brazil)

OP-26. Understanding benign T-cell infiltration in mycosis fungoides: Malignant clones are not alone
P. Vieyra-García, J. O'Malley, J. Teague, E. Lowry, R. Clark, P. Wolf (Graz, Austria – Boston, USA)

OP-27. Immunohistochemical Detection and Diagnostic Utility of T-cell Receptor Delta Chain in Cutaneous Lymphoid neoplasms
M. Pulitzer, A. Dogan, A. Chan, M. Kheterpal, P. Myskowski, A. Moskowitz, S. Horwitz, A. Jungbluth (New York, USA)

OP-28. Primary cutaneous large B-cell lymphoma, other and leg type: Clinical, morphologic, phenotypic and prognostic differences – Results of a multicenter study

C-D Klemke, M. Felcht, J.P. Nicolay, C. Weiss, C. Assaf, M. Wobser, M. Schlaak, U. Hillen, R. Moritz, I. Poor, D. Nashan, M. Beyer, E. Dippel, C.S.L. Müller, M. Sachse, F. Meiß, C. Geraud, A. Marx, S. Goerd, E. Geissinger, Werner Kempf (Karlsruhe; Mannheim; Krefeld; Würzburg; Cologne; Essen-Duisburg; Bochum; Münster; Dortmund; Berlin; Ludwigshafen; Homburg; Bremerhafen; Freiburg, Germany - Zürich, Switzerland)

10:15-10:45

Tea/Coffee Break/Poster Viewing and Exhibition

10:45-12:30 Therapeutics (III) (Chairs: James; Papadavid; Hodak)

O-49. Multimodality treatment in Sezary Syndrome combining total skin electron beam therapy and extracorporeal photopheresis with other therapies

P.A. Enz, E.A. Zambrano, A. Andrade, J.A. Baquero, A. Abeldaño, L. Mazzuocolo, (Buenos Aires, Argentina)

O-50. A meta-analysis of bexarotene response rates for cutaneous T-cell lymphoma

K.C. Fragkos (London, UK)

O-51 Valchlor gel treatment patterns from large prospective observational registry in patient with Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL)

E. Kim, G. Sharma, C. Zhao, B. Rengarajan (Frsico, USA)

O-52. Topical pimecrolimus in early mycosis fungoides: clinical and translational research

L.M. Jiménez, T. Estrach, C. Muniesa, R.F. Martínez de Misa, O. Sanmartín, F. Gallardo, B. Jiménez, M.S. Beato, M.A. Piris, P.L. Ortiz Romero (Madrid; Barcelona; Gran Canarias; Valencia; Santander Spain)

O-53. IPH4102, the first-in-class anti-KIR3DL2 monoclonal antibody, is safe and clinically active in advanced Cutaneous T-Cell Lymphoma (CTCL) patients: results from the dose-escalation part of the IPH4102-101 phase I study

M. Bagot, P. Porcu, C. Ram-Wolff, M. Khodadoust, M.B. William, M. Battistella, A. Marie-Cardine, S. Mathieu, M. Vermeer, S. Whittaker, M. Duvic, A. Bensussan, C. Paturel, C. Bonnafous, C. Bonin, F. Moriette, L. Lagache, H. Sicard, C. Paiva, K. Pilz, Y.H. Kim (Paris; Marseilles, France – Palo Alto; Jefferson; Columbus; Houston USA - Leiden, The Netherlands – London, UK)

O-54. A Multicenter Phase I dose-finding and preliminary efficacy study of the histone deacetylase inhibitor romidepsin in combination with Doxil® for the treatment of adults with relapsed or refractory cutaneous and peripheral T-cell lymphomas

W. Ai, P. Porcu, W. Berry, J. Engleman, L. Pincus, M. Wieduwilt, C-Y Yang, J. Brammer (San Francisco; Ohio; San Diego, USA)

O-55. A Randomized Phase 2 Study to Evaluate Three Dosing Schedules of Remetinostat (SHAPE), a Histone Deacetylase Inhibitor, in Patients with Stage IA- IIA Cutaneous T-Cell Lymphoma

M. Duvic, J. Guitart, A. Huen, P. Porcu, N. LeBoeuf, J. M Skolnik, K. Owen, J. Öhd, Y. Kim (Houston; Chicago; Philadelphia; Boston; Palo Alto; USA – Huddinge, Sweden)

O-56. Src is a possible therapeutic pathway in combination with HDAC inhibitors for CTCL

K. Fujii, N. Jimura, Z. Qiao, F. Kito, T. Kanekura, (Kagoshima; Tokyo Japan)

O-57. T-cell leukemia sensitivity to farnesyl transferase inhibition using Tipifarnib

R. Alonso, R. Mondejar, J.P. Vaqué, N. García, C. Pérez, F. Barrows, C. Scholz, A. Gualberto, M.A. Piris, (Santander; Madrid, Spain – La Jolla, USA)

12:30

Poster Prize and Congress Close

Poster Session

- P-01.** UK National Audit on Extracorporeal Photopheresis in Cutaneous T Cell Lymphoma
S. Sanyal, J. Scarisbrick (Birmingham, UK)
- P-02.** Comprehensive Analysis of CTCL Incidence and Mortality in Canada Reveals Changing Trends and Geographic Clustering for this Malignancy
F.M. Ghazawi, E. Netchiporouk, E. Rahme, N. Provost, D. Sasseville, I.V. Litvinov (Montreal, Canada)
- P-03.** Retinoic acid receptor agonist as monotherapy for early-stage mycosis fungoides: does it work?
I. Amitay-Laish, O. Reiter, H. Prag-Naveh, R. Kershenovich, E. Hodak (Tel Aviv, Israel)
- P-04.** Presence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma presenting in the skin
A.M.R. Schrader, P.M. Jansen, A.H.G. Cleven, J.S. Vermaat, M.H. Vermeer, R. Willemze (Leiden, the Netherlands)
- P-05.** Methotrexate in the treatment of Mycosis fungoides – a multicenter observational study in 79 patients
K. Olek-Hrab, J. Maj, E. Chmielowska, A. Jankowska-Konsur, B. Olszewska, B. Kracisz, Z. Adamski, R. Nowicki, M. Sokoowska-Wojdyao (Poznan, Poland)
- P-06.** Alemtuzumab is an Effective Tertiary Treatment vs. Single Agent Gemcitabine and Pralatrexate for Refractory Sezary Syndrome: a Systematic Review
J. Stewart, H. Wickless (Dallas, USA)
- P-07.** "You'll be fine": an artist's response to her diagnosis
D. Orłowska, J. Horton (London, UK)
- P-08.** Another prognostic factor in hydroa vacciniforme and hypersensitivity to mosquito bites: A dominant lymphocyte subset infected with Epstein-Barr virus
K. Iwatsuki, Y. Hirai, T. Miyake, H. Asada, H. Kimura, Y. Ito, A. Yachie, S. Fujiwara (Okayama, Japan)
- P-09.** ALK-positive primary cutaneous anaplastic large cell lymphoma
S. Geller, T.N. Canavan, M. Pulitzer, A.J. Moskowitz, P.L. Myskowski (New York; Birmingham, USA)
- P-10.** Synergistic Effect of Successive Administration of TTI-621 (SIRPαFc) and PEGylated Interferon-α2a in a Patient with Sézary Syndrome
O.E. Akilov, S. McCann, J.A. Thompson, C. Querfeld, M. Taylor, M. Irwin, L. Johnson, R.A. Uger, E.L. Sievers (Pittsburgh; Seattle; Duarte; Portland USA - Mississauga, Canada)
- P-11.** Therapeutic and Prognostic Significance of PARP-1 In Advanced Mycosis Fungoides and Sézary Syndrome
D. Lemchak, S. Banerjee, S.S. Digambar, B.L. Hood, T.P. Conrads, J. Jedrych, L.J. Geskin, O.E. Akilov (Pittsburgh; New York, USA)
- P-12.** An Unusual Case of Anaplastic Large Cell Lymphoma with Extensive Secondary Skin Involvement
S. Wolf, R. Goiriz, D. Paige, H. Rizvi, S. Montoto (London, UK)
- P-13.** EORTC Cutaneous Lymphoma Taskforce
M.H. Vermeer, J. Scarisbrick, E. Hodak, M. Bagot, R. Stranzenbach, R. Stadler, P.L. Ortiz-Romero, E. Papadavid, R. Knobler, P. Quaglino, S. Whittaker (Leiden, The Netherlands – Birmingham, UK - Tel Aviv, Israel – Paris, France - Minden, Germany – Madrid, Spain – Athens, Greece – Vienna, Austria – Turin, Italy – London, UK)
- P-14.** Indolent cutaneous T-cell lymphoma associated with a small number of leukemic T-cells with an aberrant immunophenotype
Y. Nakagawa, K. Manabe, T. Hamada, Y. Maeda, K. Iwatsuki (Okayama, Japan)
- P-15.** Photodynamic therapy an helpful option in difficult-to-treat areas
A. Pileri, P. Sgubbi, S.D. Infusino, S. Vaccari, A. Patrizi (Bologna; Florence, Italy)

P-16. Cutaneous T-cell lymphoma in Saudi children

Y. Binamer (Riyadh, Saudi Arabia)

P-17. Let-7 downregulation in Sézary Syndrome

D. Fanoni, L. Corti, L. Venegoni, S. Alberti-Violetti, F. Onida, E. Berti (Milan, Italy)

P-18. Malignant T cells inhibit anti-cancer and anti-infectious immunity in cutaneous T cell lymphoma

D. Ignatova, Y-TChang, R. Dummer, L.E. French, A. Cozzio, W. Hoetzenecker, E. Guenova (Zürich; St Gallen, Switzerland – Linz, Austria)

P-19. Ingenol mebutate for mycosis fungoides

D. Ignatova, Y-T Chang, E. Guenova (Zürich, Switzerland)

P-20. The incidence of adult T-cell leukemic /lymphoma with cutaneous involvement in Japan: Comparison with the prevalence of HTLV-1

T.Hamada, H. Nomura, K. Iwatsuki (Okayama, Japan)

P-21. CTCL therapy with dimethyl fumarate – clinical evaluation of the first patients treated

J.P. Nicolay, N. Maurier, K. Gülow, P.H. Krammer, S. Goerdts (Mannheim; Heidelberg, Germany)

P-22. Is illness perception a key to improve disease management in primary cutaneous lymphomas?

S.Porkert, E. Lehner-Baumgartner, J. Valencak, R. Knobler, E. Riedl, C. Jonak (Vienna, Austria)

P-23. Insect bite like reaction in a patient with chronic lymphocytic leukemia (CLL)

J. Dreier, B. Mühleisen, K.Kerl, M. Maiwald, R. Dummer, L.E. French, E. Guenova (Zürich, Switzerland)

P-24. Panel sequencing of primary cutaneous lymphomas

K. Maurus, S. Roth, S. Appenzeller, M. Goebeler, A. Rosenwald, E. Geissinger, M. Wobser (Wuerzburg, Germany)

P-25. Cutaneous involvement in T-cell prolymphocytic leukemia

A. Combalia, A. García- Herrera, E. Matues, P. Giavedoni, C. Muniesa, O. Servitje, F. Gallardo, R.M. Pujol, I. López-Lerma, T. Estrach (Barcelona, Spain)

P-26. Pegylated Interferon in Cutaneous T-cell lymphoma

Y. Binamer (Riyadh, Saudi Arabia)

P-27. Primary cutaneous gamma delta T-cell-lymphoma with a granulomatous reaction pattern

R.KC Moritz, D. Metze, J. Ehrchen, I. Oschlies (Muenster; Kiel, Germany)

P-28. Prognostic significance of Ki-67 expression in primary cutaneous T-cell lymphoma

U. Wehkamp, V. Dessert, I. Oschlies, W. Klapper, M. Weichenthal (Kiel, Germany)

P-29. Regression of a CD30-positive primary cutaneous T-cell lymphoproliferation after ribavirin treatment of chronic hepatitis E virus infection

L. Laroche, J. Bruneau, J. Zuber, Z. Belaid, A. Kraft, D. Roulot, P. Hillon, A-M.Roque, O. Hermine, V. Mallet (Bobigny; Paris; Dijon, France – Hannover, Germany)

P-30. Late recurrence of an indolent CD-8 positive lymphoid proliferation of the ear

E. Maubec, E. Marinho, L. Laroche, F. Grange, Tony Petrella (Bobigny; Paris; Reims, France – Montreal, Canada)

P-31. MYD88 L265P mutation, a diagnostic tool for specific cutaneous involvement of Waldenström macroglobulinemia

G. Bohelay, B. Husson, N. Ortonne, T. Braun, A. Levy, E. Poirier, F. Grange, E. Maubec, Liliane Laroche (Bobigny; Reims; Créteil, France)

- P-32.** Chronic profile of CD8+ T cells in peripheral blood of patients with Sezary Syndrome
M.P. Torrealba, K. Manfrere, J.F. Lima, D.R. Miyashiro, F.M.E. Teixeira, L.M. Oliveira, A.J.S. Duarte, M.N. Sato, J.A. Sanches (São Paulo, Brazil)
- P-33.** Brentuximab vedotin in an aggressive, radio and chemo-refractory PC-ALCL
M.M. Sanches, F. Gonçalves, T. Mendonça, M. Cravo, F. Sachse (Lisbon, Portugal)
- P-34.** Narrow Band UVB is a Disease modifying Therapy in Early Mycosis Fungoides or Can We Cure Early Mycosis Fungoides with Narrow Band UVB?
F. Pavlotsky, M. Dawood, A. Barzilai (Tel Aviv, Israel)
- P-35.** Cutaneous Ulcers in the Immunosuppressed
R.M. Fisher, V. Venning, E. Iermia, N. Mathe, R.N. Martin (Oxford, UK)
- P-36.** Familial mycosis fungoides: a report of 3 families from a single centre
A. Connolly, E. Calonje, W. Phillips, S. Whittaker (London, UK)